CRISPR Therapeutics AG CRSP 深 滬
等待開盤 03-26 09:30:00 美东时间
47.09
+0.660
+1.42%
華盛通- 最 高48.305
- 今 開47.25
- 成交量 107.91万股
- 最 低 47.05
- 昨 收 46.43
- 總市值 45.20亿
- 52周最高 78.48
- 市盈率 靜 --
- 換手率 1.12%
- 52周最低 30.04
- 委 比 75.00%
- 總股本 9598.53万
- 歷史最高 220.20
- 量 比 0.61
- 振 幅 2.70%
- 歷史最低 13.50
- 每 手 1
- 風險率 9.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Anti-Aging Protein Research Takes a Step Forward with Cell Cloning
Issued on behalf of Avaí Bio, Inc. VANCOUVER, BC, March 24, 2026 /PRNewswire/ -- Equity-Insider.com — A protein called α-Klotho circulating in the bloodstream protects the brain, heart, kidn...
03-24 23:05
美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
Cathie Wood's weekly recap: adds JOBY, CRSP, TEM, sells TER, TXG, CRCL
Cathie Wood’s Ark Invest reshuffled positions across its ETFs during last week, adding positions to gene-editing and AI healthcare names while trimming genomics tools and semiconductor equipment holdi...
03-16 19:05
Reported Earlier: CRISPR Therapeutics Plans $350M Convertible Note Offering, Maturing 2031, To Fund Corporate Purposes
- CRISPR Therapeutics AG (NASDAQ:CRSP) (the "Company") today announced its intention to offer, subject to market conditions and other factors, $350 million aggregate principal amount of its convertible senior notes due
03-10 21:55
BUZZ-U.S. STOCKS ON THE MOVE-Crypto stocks, MiNK Therapeutics, AtaiBeckley
BUZZ-U.S. STOCKS ON THE MOVE-Crypto stocks, MiNK Therapeutics, AtaiBeckley Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 10 (Reuters) - U.S. stock index futures ticked up
03-10 19:58
CRISPR Therapeutics stock dips on $350M convertible debt offering
CRISPR Therapeutics (CRSP) plans to offer $350M aggregate principal amount of its convertible senior notes due 2031 in a private offering. The company also expects to grant the initial purchasers a 13...
03-10 19:07
CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering
CRISPR Therapeutics AG announced plans to offer $350 million in convertible senior notes due 2031 to qualified institutional buyers under Rule 144A. The company may also grant an option to purchase up to an additional $52.5 million in notes. The notes will accrue interest semiannually and mature on March 1, 2031, unless converted, redeemed, or repurchased earlier. Proceeds will be used for general corporate purposes. The offering and sale of the ...
03-10 11:00
What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?
FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capricor, Moderna, and raising hopes for smoother drug approvals.
03-10 01:32
Why Is CRISPR Therapeutics Stock Surging Thursday?
CRSP shares jump on earnings report, strong pipeline for gene therapy. Revenue grows with increased patient treatment and analyst confidence.
02-27 02:45
Crispr Therapeutics gains amid takeover speculation
Crispr Therapeutics (CRSP) quickly rose 5% amid some takeover speculation. Vertex Pharmaceuticals (VRTX) is speculated to be the company that has been studying a potential acquisition of Crispr (CRSP)...
02-27 00:08
